VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) broadcasts the discharge of a company replace which highlights the corporate’s latest staff assembly in France, the present pipeline, and the most recent deal construction.
With the success of the licensing take care of AbbVie, the corporate wants to arrange for its subsequent part of progress.
Dr. Wolfgang Bieber reviews “In my professional opinion, as a chemist of over three decades, I’ve never seen anything like Sirona’s technology platform, which is undoubtedly revolutionary in terms of its potential to provide endless solutions to current and future pharmaceutical obstacles.”
The full company replace may be seen on the following hyperlink: https://www.sironabiochem.com/wp-content/uploads/2022/09/Sirona-Corporate-Update-September-2022.pdf
About Sirona Biochem Corp.
Sirona Biochem is a beauty ingredient and drug discovery firm with a proprietary platform know-how. Sirona makes a speciality of stabilizing carbohydrate molecules with the purpose of enhancing efficacy and security. New compounds are patented for optimum income potential.
Sirona’s compounds are licensed to main firms world wide in return for licensing charges, milestone charges and ongoing royalty funds. Sirona’s laboratory, TFChem, is in France and is the recipient of a number of French nationwide scientific awards and European Union and French authorities grants. For extra info, please go to www.sironabiochem.com.
For extra info relating to this press launch, please contact:
Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Phone: 1.450.332.6939
Email: [email protected]
Neither TSX Venture Exchange nor its Regulation Services Provider (as that time period is outlined in insurance policies of the TSX Venture Exchange) accepts accountability for the adequacy or accuracy of this launch.
———————————————
Sirona Biochem cautions you that statements included on this press launch that aren’t an outline of historic information could also be forward-looking statements. Forward-looking statements are solely predictions primarily based upon present expectations and contain recognized and unknown dangers and uncertainties. You are cautioned to not place undue reliance on these forward-looking statements, which converse solely as of the date of launch of the related info, until explicitly acknowledged in any other case. Actual outcomes, efficiency or achievement may differ materially from these expressed in, or implied by, Sirona Biochem’s forward-looking statements as a result of dangers and uncertainties inherent in Sirona Biochem’s business together with, with out limitation, statements about: the progress and timing of its scientific trials; difficulties or delays in growth, testing, acquiring regulatory approval, producing and advertising its merchandise; surprising hostile unwanted side effects or insufficient therapeutic efficacy of its merchandise that would delay or forestall product growth or commercialization; the scope and validity of patent safety for its merchandise; competitors from different pharmaceutical or biotechnology firms; and its potential to acquire further financing to assist its operations. Sirona Biochem doesn’t assume any obligation to replace any forward-looking statements besides as required by regulation.
